With the introduction of effective antidepressants, pharmacotherapy has not been limited exclusively to the psychiatrically ill, but has been expanded to include medically ill patients exhibiting depressive symptomatology as well. This has led to problems in diagnostic differentiation and, just as important, problems with interactions resulting from multiple medications. By describing the coexistence ofdepressive symptomatology in a large variety of physical illness, the physician is alerted to the complexities of psychiatric illness in the medically ill patient as well as the caution necessitated by the polypharmacotherapy required in this population.
F ollowing the introduction of imipramine, the first tricyclic antidepressant (TCA) (1) and iproniazid, the first monoamine oxidase inhibitor (MAOI) antidepressant (2) , the treatment of depression has gradually changed over the years. These two groups of drugs, together with lithium salts (3) are now the three predominant treatment modalities in depressed psychotic patients (4) . Their use, however, is not limited to this group, but has expanded to include all types of depression including those which occur in medically ill patients.
TCA's are the most extensively used antidepressants and are being prescribed with increasing frequency to patients exhibiting a wide variety of somatic symptoms. These symptoms, however, can be manifestations of a variety of conditions which are etiologically quite different: 1. Symptoms which are manifestations of medical illness mimic depressive symptomatology. 2. Symptoms which are the manifestations of a depression mimic medical illness. 3. Symptoms which are the manifestations of a depression coexistent with, or are a complication of, medical illness. In a study involving over 2,000 psychiatric outpatients, Koranyi (5) found that 43% had one or more physical illnesses. He further determined that in 51% of this group the somatic illness substantially aggravated the independent psychiatric condition; in 31% the somatic illness coexisted with the psychiatric condition and, in 18%the somatic condition was the cause of the psychiatric disorder. In support ofthis latter contention, LaBruzza (6) cited nine other studies in which the incidence of somatic illness considered causative of psychiatric disturbance ranged from 9% to 18%. Tsuang et al (7) noting that somatic and psychiatric illnesses occur together more frequently than would be expected by chance, speculated that in some instances the two illnesses could have shared etiologic factors; one illness could cause or exacerbate the other, or both illnesses could be manifestations of the same disease process.
Medical Illness Mimicking Depression
Many neurological, endocrine, nutritional and metabolic disorders produce symptoms which can be mistaken for depression, and if treated as such, remain refractory to antidepressant drugs (8) . Among the neurological disorders, some of the episodic symptoms of multiple sclerosis, such as fatigue, weakness and bizarre complaints, may be confused with depression (9) . Normal pressure hydrocephalus may resemble a form of agitated depression, while the headaches, vague paresthesias and lapses of memory following unrecognized seizures may suggest a diagnosis of depression in cases of tumors of the temporal lobe (10) .
Endocrine disorders mimic depression more frequently than neurological diseases. Patients with hypothyroidism may look depressed because of their slow movements and speech, while patients with adrenal insufficiency are often misdiagnosed as depressed because of their persistent complaints of fatigue, weight loss and diminished activity (11). The same applies to patients with hyperparathyroidism who exhibit symptoms of lethargy, fatigue and aspontaneity (12) .
Among the metabolic disorders, those with decreases in serum Na and/ or K as well as those with increases in serum Ca may simulate depression. Among the nutritional disorders, patients with anemia due to iron, folate or B 12 deficiency are frequently labelled "depression" in the early stages of evaluation. Furthermore, depressive manifestations often precede other signs of malignancies in patients with cancer of the pancreas or the gut (8) .
Depression Mimicking Medical Illness
While medical illness may mimic depression, it is considerably more frequent that depression mimic somatic illness. Hypochondriasis and psychosomatic disorders are the most common masks of depression. While no accurate prevalence figures are available, it is suspected that in the United States, one-half to two-thirds of patients over 40 years of age seen by general practitioners may suffer from masked (atypical) depression (13) . Pathognomic characteristics of masked depression are the phasic appearance of autonomic and/ or other somatic signs and symptoms, diurnal fluctuations, mild inhibition ofthe thought process and of drive, occasional dysthymic mood changes, fatigue, sleep disturbances, and an anxious sense of failure or non-specific apprehensiveness. There are indications that the incidence of masked depression as well as the incidence of patientreported somatic symptoms of depression have increased during the past 20 years.
Just as masked depression mimics medical illness, pseudodementia mimics organic dementia and may be viewed as a special form of masked depression. In the differentiation of depression and dementia the most important factors are the fluctuations in the severity of cognitive impairment in depression as compared to its constancy in dementia. Somatic symptoms such as anorexia, weight loss, insomnia and headache are typical of depression, but not of dementia. Furthermore, in depression, patients are much more apt to communicate a sense of distress and only in depression will the defects .of memory, comprehension and retention; respond to electroconvulsive therapy, TCA's or MAOI's (11).
Depression Coexistent with Medical Illness
The CNS disorders most frequently associated with depression are epilepsy, Parkinson's disease, and Alzheimer's dementia (14) . Contrary to the commonly-held belief, epilepsy is not a contraindication for the administration of TCA's, MAOI's or lithium salts. However, since TCA's tend to lower the seizure threshold, patients with seizure disorders should be given smaller doses of these antidepressants (15) . The problem is further compounded by the interaction between TCA's and phenytoin, the most extensively employed anti-convulsant. By interfering with its metabolism, TCA's produce an elevation of serum phenytoin levels and, to avoid intoxication, it may be necessary to lower the dose of the anticonvulsant (16) . There are no essential differences in epileptogenic potency among TCA's; and there is no evidence that older antidepressants (examples: amitriptyline, imipramine) produce more seizures than newer compounds (4). Since temporal lobe epilepsy is selectively worsened with lithium, it is recommended that lithium be used with caution in patients with a history of EEG abnormalities or seizures (17) .
It is not infrequent that patients with Parkinson's disease are depressed. Levodopa, the drug most widely used in the treatment of Parkinson's disease may, by increas-ing the level of catecholamines, have an alleviating effect on depressive mood or, by decreasing serotonin, have an aggravating effect on mood. While concomitant administration oflevodopa and an MAOI may cause a significant rise in blood pressure, prolonged concomitant administration of an antiparkinson agent with a TCA may produce excessive anticholinergic effects. To prevent this, it is advisable to decrease the dose of the anti parkinson drug or choose a TCA with a low anticholinergic potential. Among the various TCA's, protriptyline possesses the lowest and amitriptyline the highest anticholinergic effects; and, among the anti parkinson drugs, amantadine lacks anticholinergic effects altogether (18) .
The same considerations need to be given in Alzheimer's dementia. Since elderly patients have a decreased ability to metabolize TCA's and are extremely sensitive to their anticholinergic effects, the dose of antidepressant medication should always be kept low in patients with Alzheimer's dementia. In this context, one should not overlook the fact that the anticholinergic action of MAOI's is considerably lower than that of TCA's (14) .
Ocular and Oral Diseases
Precipitation of an acute narrow angle glaucoma with TCA's is rare and with MAOI's it is even rarer. Therefore, chronic glaucoma which can be managed with cholinergic eye drops is not a contraindication for the use of these drugs (18) .
Similarly, dental caries are not a contraindication for TCA's despite the fact that they may induce or aggravate dry mouth. Fluoride lozenges are preferable to sugar-free candy or gum for the symptomatic relief or dry mouth when dental carries are a problem (19) .
Endocrine Disorders Thyroid Disorders
Lithium interferes with several steps in the synthesis of hormones of the thyroid gland. As a result, approximately five percent of patients on long-term lithium treatment develop goiter and somewhat less than one percent hypothyroidism. Since thyroid enlargement might be associated with increased, though subclinical, thyroid stimulating hormone (TSH) levels, an exaggerated TSH response to the administration of thyrotropinreleasing hormone (TRH) provides a diagnostic test. In spite of their rather frequent occurrence, it is seldom necessary to discontinue lithium therapy because of these endocrine changes. Administration oflevothyroxine (100 to 150 tag] day) is usually sufficient treatment. Furthermore, since potassium or other iodides may potentiate hypothyroid and gasterogenic effects, patients on lithium therapy should be advised to avoid both over-the-counter and prescription compounds containing iodides (20) . Although lithium reduces synthesis, administration of thyroid hormones such as triiodothyronine (25 tug] day) may shorten the usual time lag between the initiation of TCA treatment and the appearance of therapeutic effects (18) .
Contraceptives
Administration of oral contraceptives, especially in the older, strongly progesteronal preparations, may induce depression. This effect is complicated by the fact that oral contraceptives enhance the metabolism and lower the plasma level of TCA's (8) .
Menopause
Although combined administration of a TCA and estrogen may induce lethargy, estrogen (2 fJ.g/ day) given to menopausal or post-menopausal women has been found to improve well-being and mental performance in patients (8, 18) .
Diabetes Mellitus
In a sample of 203 manic-depressive patients, Lilliker (21) found the incidence of diabetes to be almost 10% in contrast to the population rate of approximately 2%. This rate was higher in female manic-depressives and was almost four times higher than the rate found in schizophrenics.
MAOI's significantly modify the response to insulin. Hydrazines potentiate and prolong insulin-induced hypoglycemia, while non-hydrazines only delay the time of recovery. To prevent severe hypoglycemia, stupor and/ or hypotensive collapse, the dosage of insulin should be reduced in depressed diabetics when an MAOI is added to the treatment regime (22) .
Gastrointestinal Disorders
Although pyrosis commonly occurs, treatment with TCA's produces a reduction of gastric secretion and acid production, together with a slowing of gastric emptying and small bowel transit time -all of which may have a favorable effect on gastric ulcer patients. While the druginduced relaxation of the esophageal sphincter may aggravate hiatal hernia, the drug-induced decrease of intestinal motility may result in constipation which, if ignored, can lead to an adynamic ileus with resultant serious consequences (23, 24) .
Gastrointestinal irritation occurs in approximately 50 percent of patients at the beginning of treatment with lithium salts, and there may be an aggravation oflatent or overt gastrointestinal disease. Patients with regional ileitis frequently develop severe and persistent diarrhea. Nevertheless, the presence of gastrointestinal disease is not necessarily a contraindication oflithium therapy and, in fact, peptic ulcer and/ or ulcerative colitis may improve in the course oftreatment (18) .
Cardiovascular Disease
In spite of their effect on the cardiovascular system, tricyclic and MAOI antidepressants should not be withheld from cardiac patients. However, when evident, cardiac decompensation should be treated prior to commencement of therapy. In case of ischemic chest pain, concurrent administration of a {3-adrenergic receptor blocker may be necessary (25) . With both drugs one should start with a low dose (example: imipramine, 10mg tid and propranolol, 10 mg tid), and depending on the patient's tolerance, increase daily Oreven less frequently until therapeutic dose levels are attained.
Because of their quinidine-like action, TCA's should be used with caution in patients with changes in cardiac conduction. It should also be borne in mind that TCA's interact significantly with antidysrhythmic drugs, such as procainamide (26) .
Cardiovascular disease is not a contraindication for lithium treatment. However, since lithium may induce T-wave changes without prolongation of the QT interval, electrocardiographic monitoring is advisable. Lithiuminduced dysrhythmia is rare and there is a prompt normalization of the EKG after discontinuation of therapy (27) .
Myocardial Infarction
When necessitated by severe depression occurring in the month following a heart attack, electroconvulsive therapy is the treatment of choice. Among the various antidepressants, doxepin is usually given preference for patients with conduction defects.
Hypertension
TCA's inhibit the uptake of guanethidine and its congeners into the neuronal terminal. By preventing accumulation at these action sites, TCA's antagonize the antihypertensive effect of these drugs. Since doxepin at low doses (100 mg per day) does not appear to block the antihypertensive effect, it is the drug of choice for concurrent therapy with guanethidine. Clonidine,like guanethidine, may cause a paradoxical rise in blood pressure.
Since administration of reserpine Or methyldopa may induce depression, treatment with these substances may prevent and/ Or interfere with the therapeutic effect of TCA's. Conversely, TCA's may intensify the hypotensive effects of both reserpine and methyldopa as well as the hypotensive effects of thiazide diuretics.
Hepatic Insufficiency
TCA's are primarily metabolized in the liver, and with chronic liver disease, their concentrations increase. Consequently, in hepatic insufficiency there is a marked CNS sensitivity and intolerance to TCA's (14) . Insofar as MAGI's are concerned, the PDR warns that phenelzine should not be given to patients with a history of liver disease Or with abnormal liver function tests, although phenelzine as a rule does not impair hepatic function, but rather, on rare occasions has been associated with allergic hepatitis.
Renal Insufficiency
In contrast to hepatic insufficiency, TCA's are welltolerated in patients with renal damage. There is, however, increased CNS sensitivity to these drugs.
Although lithium is almost exclusively excreted by the kidneys, lithium therapy is not contraindicated in patients with renal disease. However, in case of an increase in serum creatinine or blood urea concentrations, a creatinine clearance test is mandatory. Ifthere is a significant reduction in creatinine clearance, serious consideration must be given to discontinue lithium therapy (28) .
There are different types of interactions between diuretics and lithium salts. While thiazides, loop diuretics (furosemide and ethacrynic acid), potassium-sparing diuretics (spironolactone and triamterene) and diuretics with a site of action distal to the proximal tubules may cause lithium retention and an increase in serum lithium levels, oscmotic diuretics (mannitol and urea), carbonic anhydrase inhibitors (acetazolamide) and diuretics with a proximal tubular action site may have the opposite effect. Hence lithium dosage needs to be titrated to keep serum lithium levels unchanged (29) .
Genito-urinary System
TCA's may induce urinary retention in patients with prostatic hypertrophy. Since the retention is promptly relieved by the administration of bethanechol (25 mg tid orally), prostatic hypertrophy is not a contraindication for treatment with TCA's.
Difficulties in achieving and maintaining an erection are sometimes seen in lithium-treated patients, while delayed or retrograde ejaculation in the male and inability to achieve orgasm in the female are occasionally encountered in patients treated with MAOI's. Since drug-induced sexual dysfunctions readily remit with a lowering of the dose, only in exceptional cases is it necessary to discontinue treatment in those patients (30) .
Pain and Rheumatoid Arthritis
It has long been recognized that there is an association between chronic pain and depression, and patients with chronic pain frequently respond favorably to the administration of a TCA.
While neuroleptics may potentiate the therapeutic effect of narcotic analgesics in the management of persistent pain (example: inoperable cancer), combined administration of a neuroleptic and a TCA may be therapeutically effective without a narcotic analgesic in the treatment of denervation dysesthesias, such as postherpetic neuralgia, anesthesia dolorosa, peripheral neuropathy. The analgesic action can also be potentiated by the addition of an antihistaminic drug (31) .
Facial pain and muscular contraction headache characterized by bilateral symmetrical tension in the frontal and occipital muscles seem to be particularly responsive to antidepressant drugs. Taking into consideration that these patients are prone to become addicted to analgesics, one should not withhold the prescription of an antidepressant too long, especially in patients whose sleep is disturbed.
Antidepressants may also have a favorable therapeutic effect on the pain associated with rheumatoid arthritis. While TCA's decrease the gastrointestinal absorption of phenylbutazone, a drug used in the treatment of rheumatoid arthritis, they increase blood levels by interfering with the metabolism of the drug (32) .
Phenylbutazone, as well as indomethacin, reduce renal lithium clearance and increase tubular reabsorption. Administration of these anti-inflammatory agents may increase lithium 'concentration to the point of intoxication (33) .
Conclusions

Pharmacological Properties
Medical illness per se is not a contraindication of pharmacotherapy for depression. However, in medically ill patients careful attention needs to be paid to the pharmacological properties of antidepressant drugs (examples: sedation, histamine (HI) receptor blockage, anticholinergic potency and protein-binding capacity).
Most sedating among the TCA's is doxepin, followed by amitriptyline and trimipramine; the least sedating is protriptyline, followed by desipramine. Indeed, there are indications that protriptyline may exert some mild stimulating action. HI-receptor blockage may account for the sedating effect ofTCA's and contribute to their hypotensive and appetite-stimulating action. Among the various TCA's doxepin is by far the most strongly antihistaminic, followed by amitriptyline. Other TCA's are considerably less potent HI-receptor blockers (34) .
A rough ranking of anticholinergic potency of TCA's based on central and peripheral muscarinic cholinergic receptor binding is as follows: amitriptyline, doxepin, trimipramine, imipramine, nortriptyline and desipramine. Amitriptyline is 20 times more potent in blocking muscarinic acethylcholine receptors than protriptyline or desipramine (35) .
Using an ultrafiltration technique with labeled compounds, protein-binding capacity is estimated at 96% for imipramine and amitriptyline, 95% for nortriptyline, 92% for protriptyline and 90% for desipramine. Proteinbinding varies among individuals and this variation explains, in part, some of the difficulties encountered in correlating plasma concentrations with clinical response (36) .
Clinical Effects
Irrespective of pharmacological considerations, the three major groups of drugs used in the treatment of depression differ in their clinical effect. While TCA's are considered to be the first choice of treatment for all depressions, the proven indication for these drugs is primary endogenous (major) depression, characterized by psychomotor retardation, anorexia, weight loss, and sleep disturbance. The chances for favorable response are considerably reduced in patients with prior episodes of illness, delusions, neurotic, hysterical and/ or hypochondriacal traits.
While some consider MAOI's as a second choice of treatment in depression and prescribe MAOI only when a TCA has failed, sufficient clinical experience has accum-ulated for the use of a MAOI as the primary therapy for patients with atypical depression characterized by hyperphagia, hypersomnolence, hyperactivity, anxiety, fatigue, phobia and various somatic complaints.
There are also indications that there is a group of patients who are unresponsive to antidepressants, but are responsive to lithium salts. Common characteristics of this group are anergia, hypochondriasis, obsessive traits and a positive family history of endogenous depression.
Drug Therapy versus Other Treatments
While modern pharmacotherapy has opened new perspectives for treating depression, the fact remains that only approximately 70% of depressed patients respond favorably to the initial pharmacological approach. In this context, it should be noted that in the early 19th century depression was commonly treated with combined physical (warm bath) and moral treatment with a similar success rate as measured by discharge from the hospital (37) . Undoubtedly, modern pharmacological treatments are superior to a warm bath and moral treatment in reducing the time required for recovery, but they should only be prescribed for medically ill patients after careful consideration has been given to the risk-benefit ratio.
